There is a patent dispute between Doudna’s research team and the Broad Institute (MIT and Harvard) over the invention of CRISPR-Cas9 technology for use in human cells. The US patent granted to the Broad Institute is under appeal. The European patent office has revoked this first patent obtained by the Broad Institute citing lack of novelty. The European patent office has granted patents to the University of CaliforniaCalifornia and University of Vienna. One for using the CRISPR-Cas9 system across prokaryotic and eukaryotic systems and another for a modified form of CRISPR-Cas9 to regulate gene expression. Numerous patents have been assigned to Caribou Biosciences for CRISPR-Cas9 adaptations and other molecular biology materials.
Naval Ravikant is the CEO and a Co-Founder of AngelList, a website for startups and startup investors. He previously founded Vast, a vertical search engine and Epinions, a crowdsourced reviews site (acquired by Shopping.com) and managed "Hit Forge," a successful early-stage investment fund that invested in early rounds of Uber, Twitter, Wish and Thumbtack. He was named Angel InvestorAngel Investor of the Year by TechCrunch and received a Crunchie award. Naval was previously a Venture Partner at August Capital.